Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
about
The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2SLC transporters as therapeutic targets: emerging opportunitiesDopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?Morphological and functional imaging in neurological and non-neurological Wilson's patients.Neuroimaging in spasticity and movement disorders.Automated Analysis of (123)I-beta-CIT SPECT Images with Statistical Probabilistic Anatomical MappingHow useful is [123I]beta-CIT SPECT in clinical practice?Manganese: recent advances in understanding its transport and neurotoxicityBrain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT Findings in a Patient with Wilson Disease: A Case Report.Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.Occupancy of the Zinc-binding Site by Transition Metals Decreases the Substrate Affinity of the Human Dopamine Transporter by an Allosteric Mechanism.Misidentification of Wilson Disease as Schizophrenia (1998-2013): Case Report and Review.Absence of nigrostriatal degeneration in LEC rats up to 20 weeks of age.Sleep disorders in Wilson's disease.Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease.Coexisting Parkinson's and Wilson's Disease: Chance or Connection?Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study.Psychopathology and personality traits in patients with treated Wilson disease grouped according to gene mutations.Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease.
P2860
Q27011665-7F181D23-00FF-4235-80FA-63543DCB7088Q27014726-504B5203-0FCE-4AD0-BFFF-24CF81D7F3E2Q30703259-3DB4AC46-3100-4CF6-BA47-D625C5F4B2BEQ30748092-014A3946-701C-42A1-9412-56581B12A89AQ30844890-7ACDFA04-BB99-41E4-B921-B606E564828FQ33669839-B4B7BC73-BD40-4E63-8E76-BD01134E4C46Q35489842-E1563905-3408-426E-BBDA-AA9DF2A931C0Q35946187-303AAFB8-89D1-40DF-A7A7-200CBF9F4882Q36064595-8FEF645F-3A6B-4E99-87FF-9F1EB780B583Q36590927-E296F247-0510-4C38-BA74-9C1D7408292CQ42315857-BDC203A3-0DE5-430D-81E2-0B94CC47A480Q46329937-210B6EFA-11AD-40F9-8CBE-7FA216521212Q46539519-46D0B3BB-0831-454E-9291-E6AFF86DC586Q48353921-436D0969-473B-4EFF-80DB-A77A92965DE0Q48967058-D92E0BBE-1312-4C80-88FA-62E6D3EC4B56Q50224412-60129985-FD87-42A5-9040-D196570D8DFBQ50246509-C3C5BB04-31B2-4272-A147-D8B0799912E8Q51890049-E2B1FED9-98A9-419E-A5F8-6DC91F22C08FQ53442662-728C3BC7-2B78-4A85-BD89-DE3701F45B3A
P2860
Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@ast
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@en
type
label
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@ast
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@en
altLabel
Dopamine transporter imaging w ...... gic damage in Wilson's disease
@en
prefLabel
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@ast
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@en
P2093
P2860
P356
P1476
Dopamine transporter imaging w ...... ic damage in Wilson's disease.
@en
P2093
P2860
P356
10.1136/JNNP.65.1.60
P407
P577
1998-07-01T00:00:00Z